Healthcare / BiotechnologyNSE
$447.50
+0.85 (+0.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $669.6M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$77.6B
P/E
31.3x
↑EV/EBITDA
21.3x
↑ROE
18.2%
↑Gross Margin
54.0%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+9.6%
FCF CAGR
+11.7%
FCF margin
12.1%
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.47B · net income $2.48B · FCF $1.15B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.47B | $9.47B | $10.30B | $7.10B | $7.21B |
| Net Income | $2.48B | $2.48B | $3.05B | $1.64B | $1.60B |
| EBITDA | $3.63B | $3.63B | $4.24B | $2.48B | $2.43B |
| EPS | 14.29 | 14.29 | 17.59 | 9.44 | 9.23 |
| Gross Margin | 54.0% | 54.0% | 55.2% | 54.9% | 52.2% |
| Operating Margin | 28.5% | 28.5% | 34.9% | 28.5% | 26.9% |
| Net Margin | 26.2% | 26.2% | 29.6% | 23.1% | 22.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.00 | 0.01 |
| Current Ratio | 4.21 | 4.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.15B | $1.15B | $-341.1M | $669.6M | $822.9M |
| Returns | |||||
| ROE | 18.2% | 18.2% | 26.9% | 19.4% | 23.5% |
| Valuation | |||||
| P/E | 31.32 | 31.32 | 41.28 | 43.83 | — |
| EV/EBITDA | 21.34 | 21.34 | 29.69 | 28.74 | — |
| P/B | 5.71 | 5.71 | 11.12 | 8.49 | — |
| Growth & Yield | |||||
| Revenue Growth | -8.0% | -8.0% | 45.0% | -1.4% | — |
| EPS Growth | -18.8% | -18.8% | 86.3% | 2.3% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
40.6%
EPS terminal req.
$39.71
Spread vs growth
-59.3%
5Y implied EPS CAGR
27.4%
EPS terminal req.
$48.05
Spread vs growth
-46.2%
10Y implied EPS CAGR
18.4%
EPS terminal req.
$77.38
Spread vs growth
-37.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-48.8%
Start / end P/E
49.9x → 31.3x
EPS bridge
17.59 → 14.29
Residual
+7.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.